Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat.

The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5-25 ng/kg) and C18-PAF (2.5-200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6-15%) before causing dose-dependent systemic hypotension (2-64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-DPAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25-200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.
AuthorsR K Handa, J W Strandhoy, V M Buckalew Jr
JournalLife sciences (Life Sci) Vol. 49 Issue 10 Pg. 747-52 ( 1991) ISSN: 0024-3205 [Print] ENGLAND
PMID1875784 (Publication Type: Journal Article)
Chemical References
  • Antihypertensive Agents
  • Platelet Activating Factor
  • Vasodilator Agents
  • Anesthesia
  • Animals
  • Antihypertensive Agents
  • Blood Pressure (drug effects)
  • Kidney (blood supply)
  • Male
  • Muscle Relaxation (drug effects)
  • Muscle, Smooth, Vascular (drug effects)
  • Platelet Activating Factor (pharmacology)
  • Rats
  • Rats, Inbred Strains
  • Regional Blood Flow (drug effects)
  • Vasodilator Agents

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: